Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) will release its first quarter 2026 financial results after markets close on April 21, 2026. Management will host a conference call and concurrent webcast the same day at 4:30 PM ET (1:30 PM PT) to review Q1 2026 performance.
The live webcast link and archived replay will be available in the Investors & Events section at the company website, and phone access requires registration for dial-in details and a personal PIN.
Positive
- None.
Negative
- None.
News Market Reaction – BBNX
In the Mar 31 session, BBNX gained 1.62%, reflecting a mild positive market reaction. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Conference appearance | Positive | +1.8% | Announced TD Cowen healthcare conference presentation with webcast access. |
| Feb 17 | Earnings & guidance | Positive | -2.6% | Reported strong 2025 growth and introduced 2026 revenue and margin guidance. |
| Jan 08 | Preliminary earnings | Positive | -37.0% | Released preliminary Q4 2025 topline financial results and key operating metrics. |
| Dec 08 | Earnings pre-announcement | Neutral | -3.6% | Planned pre-release of Q4 2025 topline results and investor meetings schedule. |
| Nov 03 | Conference participation | Positive | +0.4% | Outlined participation in two upcoming healthcare investor conferences with webcasts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: strong operational growth and guidance updates have sometimes been followed by negative price moves, while conference-related announcements have seen modest positive or flat reactions.
Over the last six months, Beta Bionics has focused on investor outreach and transparent financial communication. It pre-announced Q4 2025 topline metrics in Dec 2025, then provided preliminary results in Jan 2026 and full 2025 results plus $130M–$135M 2026 revenue guidance in Feb 2026. Investor conference appearances in Nov 2025 and Feb 2026 supported visibility. Today’s earnings-date announcement fits this pattern of scheduled updates ahead of detailed financial disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s first quarter 2026 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BIe6169095850a4ded9529fe8fccd41156
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
